SCHEMBL4602900

SCHEMBL4602900

CN(C)CCCCCCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCCCCCCN(C)C

nearest known ligand 0.65

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.65
TSHR P16473 1/20 0.65
DNM1 Q05193 3/20 0.52
KDM4E B2RXH2 3/20 0.45
SIGMAR1 Q99720 2/20 0.43
LSS P48449 1/20 0.40
HTR1B P28222 1/20 0.38
MEN1 O00255 1/20 0.37
THRB P10828 1/20 0.37
HTT P42858 1/20 0.37
KMT2A Q03164 1/20 0.37
MAPT P10636 1/20 0.37
SMN1; SMN2 Q16637 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL811337 1.00 ALDH1A1 (0.65) ALDH1A1TSHRDNM1KDM4ESIGMAR1
Potassium SCHEMBL5226056 0.97 ALDH1A1 (0.61) ALDH1A1TSHRDNM1KDM4ESIGMAR1
Potassium SCHEMBL5227850 0.97 ALDH1A1 (0.61) ALDH1A1TSHRDNM1KDM4ESIGMAR1
SCHEMBL7763390 0.97 ALDH1A1 (0.59) ALDH1A1TSHRDNM1KDM4ESIGMAR1
SCHEMBL22813038 0.94 ALDH1A1 (0.56) ALDH1A1TSHRDNM1KDM4ESIGMAR1
SCHEMBL9651294 0.91 ALDH1A1 (0.50) ALDH1A1TSHRDNM1KDM4ELSS
SCHEMBL21657557 0.90 DNM1 (0.64) ALDH1A1TSHRDNM1KDM4ESIGMAR1
SCHEMBL9549392 0.90 DNM1 (0.71) ALDH1A1TSHRDNM1KDM4ELSS
SCHEMBL21657553 0.90 DNM1 (0.71) ALDH1A1TSHRDNM1KDM4ELSS
SCHEMBL21657548 0.90 DNM1 (0.56) ALDH1A1TSHRDNM1KDM4ESIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080227865-A1 COLIPSE-LIPASE INHIBITORS IN THE PREPARATION OF A PHARMACEUTICAL COMPOSITION IN ORDER TO PREVENT OBESITY FORSKARPATENT I SYD AB (SE) 2008-09-18 US claimed
US-7425577-B2 Lipase-colipase inhibitor FORSKARPATENT 1 SYD AB (SE) 2008-09-16 US claimed
EP-1660062-B1 USE OF COLIPASE-LIPASE INHIBITORS IN THE PREPARATION OF A PHARMACEUTICAL COMPOSITION IN ORDER TO PREVENT OBESITY FORSKARPATENT I SYD AB (SE) 2008-07-09 EP claimed
US-20060199869-A1 Lipase-colipase inhibitor FORSKARPATENT 1 SYD AB (SE) 2006-09-07 US claimed
US-20080227865-A1 COLIPSE-LIPASE INHIBITORS IN THE PREPARATION OF A PHARMACEUTICAL COMPOSITION IN ORDER TO PREVENT OBESITY FORSKARPATENT I SYD AB (SE) 2008-09-18 US disclosed
US-7425577-B2 Lipase-colipase inhibitor FORSKARPATENT 1 SYD AB (SE) 2008-09-16 US disclosed
EP-1660062-B1 USE OF COLIPASE-LIPASE INHIBITORS IN THE PREPARATION OF A PHARMACEUTICAL COMPOSITION IN ORDER TO PREVENT OBESITY FORSKARPATENT I SYD AB (SE) 2008-07-09 EP disclosed
US-20060199869-A1 Lipase-colipase inhibitor FORSKARPATENT 1 SYD AB (SE) 2006-09-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060199869-A1 Lipase-colipase inhibitor PNLIP, LPL, LIPC ALDH1A1 1110/4885TSHR 3500/4885DNM1 3975/4885
US-20080227865-A1 COLIPSE-LIPASE INHIBITORS IN THE PREPARATION OF A PHARMACEUTICAL COMPOSITION IN ORDER TO PREVENT OBESITY PNLIP, LIPE, LPL ALDH1A1 1476/4885TSHR 3919/4885DNM1 4358/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.